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Because of its stimulating eﬀect on RBC production, erythropoietin (Epo) is used to treat anemia, for example, in patients on
dialysis or on chemotherapy. In β-thalassemia, where Epo levels are low relative to the degree of anemia, Epo treatment improves
the anemia state. Since RBC and platelets of these patients are under oxidative stress, which may be involved in anemia and
thromboembolic complications, we investigated Epo as an antioxidant. Using ﬂow-cytometry technology, we found that in vitro
treatmentwithEpoofbloodcellsfromthesepatientsincreasedtheirglutathionecontentandreducedtheirreactiveoxygenspecies,
membrane lipid peroxides, and external phosphatidylserine. This resulted in reduced susceptibility of RBC to undergo hemolysis
and phagocytosis. Injection of Epo into heterozygous (Hbbth3/+) β-thalassemic mice reduced the oxidative markers within 3 hours.
Our results suggest that, in addition to stimulating RBC and fetal hemoglobin production, Epo might alleviate symptoms of
hemolytic anemias as an antioxidant.
1.Introduction
Erythropoietin (Epo), a hormone released upon hypoxia
mainly in the kidneys, enhances red blood cell (RBC)
production (erythropoiesis) by stimulating the proliferation
of erythroid progenitors and precursors in the bone marrow
[1,2].ThiseﬀectismediatedbyahomodimericEporeceptor
(EpoR), a class 1 cytokine receptor [3]. Recombinant human
Epo is widely used for the treatment of anemia, for example,
in patients on chemotherapy [4] or on hemodialysis [5–7].
Treatment with Epo was also tried experimentally in patients
withthalassemia[8–11].Inthesepatients,inspiteofthestate
of chronic anemia, the level of Epo is usually low relative
to the degree of anemia [12, 13]. Administration of Epo
to splenectomized patients with β-thalassemia intermedia
resulted in a dose-dependent improvement in their anemia
[14, 15]. A long-acting Epo (darbepoetin alfa) was shown
to substantially increase hemoglobin (Hb) levels in patients
with HbE-β-thalassemia [16].
Although the main eﬀect of Epo is related to stimulation
of erythropoiesis, it was suggested that in patients with
chronic renal failure on dialysis its anti anemia eﬀect may
also be associated with increasing the survival of mature
red blood cells (RBC) [17]. It was reported that in such
patients, the increased number of RBC exhibiting surface
phosphatidylserine (PS), a marker of senescence [18–20],
was reduced within 4hrs after administration Epo [20].
PS is increased in RBC following several stress situations,
including oxidative stress [21]. We have shown that RBC
and platelets from patients with β-thalassemia are under
oxidative stress; they demonstrate an increased reactive
oxygen species (ROS) and a decreased content of reduced
glutathione (GSH), the main cellular antioxidant, than their
normal counterparts [22]. This oxidative stress resulted in
membrane lipid peroxidation and exposure of PS. The latter
is considered a major factor in shortening the life-span of
RBC [18] and hyperactivation of platelets from thalassemic
patients [23].
We now investigated the in vitro eﬀect of Epo on the
oxidative status of RBC and platelets from β-thalassemic
patients and the in vivo eﬀect on these cells of Epo
administration in β-thalassemic mice. The results show that
Epo has an antioxidative eﬀect in both RBC and platelets by
which it may beneﬁt thalassemic patients.2 Anemia
2.MaterialsandMethods
2.1. Patients’ Blood Samples. Peripheral blood samples were
obtained from normal donors and patients with β-thalasse-
miaintermediaandmajor.Thepatients’mutationsandsome
relevant clinical parameters (e.g., transfusion and chelation
therapy) were recently summarized [24]. In polytransfused
patients, blood samples were obtained before transfusion,
that is, at least 3 weeks following the previous transfusion.
These experiments were approved by the Hadassah-Hebrew
University Medical Center Ethical Committee of Human
Experimentation and are in accordance with the Helsinki
Declaration of 1975. Informed consent was obtained in all
cases.
Blood samples were collected in EDTA-containing tubes
(Becton Dickinson, Plymouth, UK) and were washed twice
and resuspended in Ca++-a n dM g ++-free Dulbecco’s Phos-
phate Buﬀered Saline (PBS) (Biological Industries, Kibbutz
Beit-Haemek, Israel) to a concentration of 4 × 106 RBC/ml.
Within 2hrs of blood withdrawal, the cells were incubated
at 37◦Ci na5 %C O 2 incubator with human recombinant
erythropoietin(Epo,CilagAG,Schaﬀhausen,Switzerland)at
doses and duration indicated in the text.
2.2. Mice. The founders of a thalassemic mouse colony
were obtained from Dr. S. Rivella, Weill Medical College
of, Cornell University, NY, NY. Heterozygous (Hbbth3/+)
mice, exhibit severe anemia (7 to 9g/dL Hb), abnormal
RBCmorphology,splenomegaly,andhepaticirondeposition
[25]. Animals were bred at the animal facility of the Sharett
Institute, Hadassah Hospital, Jerusalem, Israel. Four-month-
old mice were intraperitoneally inoculated with Epo (5
000U/kg). Blood samples (20μL) were collected from their
tail vein before and 2hrs after treatment. These experiments
were approved by the Hadassah—Hebrew University Medi-
cal Center Animal Ethics Committee.
2.3. Assays for RBC Hemolysis and Phagocytosis. RBC (5 ×
106/mL) were washed and suspended in PBS, and incubated
overnight. RBC were then centrifuged, resuspended in PBS
and counted. Hemolysis was calculated as percentage of
lysed RBC compared with the RBC input. The results were
conﬁrmed by spectrophotometric measurement [26] of the
Hb content in the hemolysate.
To measure phagocytosis, 5 × 106/mL RBC diluted in
PBS were added to macrophage cultures prepared as pre-
viously described [24]. After overnight incubation at 37◦C,
thenonphagocytosedRBCwereharvestedbycarefulwashing
and counted microscopically using a hemocytometer. The
percent of phagocytosed RBC was calculated per the RBC
input.
2.4. Flow Cytometry Measurements of Oxidative Stress Mark-
ers. Oxidative stress markers were measured as previously
described [22, 27, 28] in mixtures of RBC and platelets.
ROS was measured following incubation for 15min with
0.4mM 2 -7 -dichloroﬂuorescin diacetate (DCF) (Sigma, St.
Louis, MO). Membrane lipid peroxides were measured
following 1-hour incubation with 40μM N-(ﬂuorescein-5-
thiocarbamoyl)1,2-dihexadecanoyl-sn-glycero-3-phosphoe-
thanolamine, triethylammonium salt (ﬂuor-DHPE) (Mole-
cular Probes Inc., Eugene, OR). For measurement of calcein
uptake, the cells were incubated for 15min with 0.5μM
calcein acetoxymethyl ester (Sigma). Incubations were car-
r i e do u ta t3 7 ◦C in a humidiﬁed 5% CO2 incubator. For
measuring external phosphatidylserine (PS) the cells were
washed and resuspended in 100μL calcium-binding buﬀer
((10mM HEPES, 140mM NaCl and 2.5mM CaCl2 (pH
7.4)) and stained for 20min at room temperature with
5μL FITC-Annexin V (IQ products, Groningen, The
Netherlands).
The GSH content was measured by spinning the cells
down and incubating the pellet for 3min. at room temper-
ature with 40μM (ﬁnal concentration) of mercury orange
(Sigma).A1mMstocksolutionofmercuryorangewasmade
up in acetone and stored at −20◦C. The cells were then
washed and resuspended in PBS.
Following treatments as indicated above the cells were
analyzed with a Fluorescence-Activated Cell Sorter (FACS-
calibur, Becton-Dickinson, Immunoﬂuorometry systems,
Mountain View, CA). Instrument calibration and set-
tings were performed using CaliBRITE-3 beads (Becton-
Dickinson). The cells were passed at a rate of ∼1000 per
second, using saline as the sheath ﬂuid. A 488nm argon
laser beam was used for excitation. RBC and platelets were
gated based on their size (forward light scatter, FSC) and
granularity (side light scatter, SSC) as previously described
[27]. The identity of each cell population was veriﬁed by
stainingwithantibodiestoglycophorin-AandCD41forRBC
and platelets, respectively [29]. For every assay, unstained
cells, both treated and nontreated, were used as controls. The
Mean Fluorescence Intensities (MFIs) and the percentages
of positive cells were calculated using the FACS-equipped
CellQuestR software. The results are expressed as the average
±standarddeviation(SD)MFIandcomparedusingthetwo-
sample Student’s t-test for diﬀerences in means.
3. Results
The ﬂow cytometry analysis of the inﬂuence of Epo on
the intracellular content of ROS in thalassemic RBC and
p l a t e l e t si se x e m p l i ﬁ e di nFigure 1. Diluted blood samples
weretreatedwithEpo(1U/ml)for2hrsat37◦C,stainedwith
DCF and then stimulated with H2O2 (1mM). Figure 1(a)
shows a FSC × SSC dot plot. Gates were set on platelets
(R1) and RBC (R2) based on their size (FSC) and granularity
(SSC). The DCF-ﬂuorescence histograms of the gated RBC
(Figure 1(b)) and platelets (Figure 1(c)), untreated (grey
histograms) or treated with Epo (white histograms), as well
as their MFI are shown. Epo-treated RBC and platelets in
this sample had 2.9-fold and 3.75-fold lower ROS levels,
respectively, compared with nontreated cells.
A representative kinetics experiment of Epo eﬀect on
ROSgenerationbyRBCandplateletsispresentedinFigure 2.
A blood sample obtained from a thalassemia patient was
stained with DCF, washed, and then incubated at room
temperature with Epo (1U/ml). The time-related changes inAnemia 3
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Figure 1: Flow cytometry analysis of the Epo eﬀect on ROS generation by RBC and platelets. A diluted blood sample obtained from a
thalassemia patient was treated for 2hrs with Epo (1U/ml) at 37◦C, stained with DCF and then stimulated with 1mM H2O2 for 15min. (a)
FCSversusSSCdotplot.Thegatesindicatethepositionofplatelets(R1)andRBC(R2).(b-c)DistributionhistogramsshowingDCF-derived
ﬂuorescence (FL-1) of untreated (grey) and Epo-treated (white) RBC (b) and platelets (c). The mean ﬂuorescent intensity (MFI) of each
population is indicated.
theﬂuorescenceofeachpopulationareindicated.Theresults
indicate that the antioxidative eﬀect of Epo starts within
10–15min. Similar results were obtained in 3 additional
experiments with cells derived from diﬀerent patients.
The eﬀe c to fE p oo nR O Sa n dG S Ho fb l o o dc e l l s
obtained from 11 patients with β-thalassemia is summarized
in Figure 3. On the average, Epo reduced ROS in RBC and
platelets by 1.5- to 2-fold (P<. 005) (Figures 3(a) and
3(b)). The eﬀect was noted in nonstimulated (Figures 3(a)
and 3(b))a n dH 2O2-stimulated cells (Figures 3(c) and 3(d)),
indicating that Epo decreased the cells’ basal ROS as well as
their ability to generate ROS in response to an oxidant. The
ﬁgurealsoshowsthatEpotreatmentincreasedtheGSHlevels
by 1.25-fold in both RBC and platelets (P<. 01) (Figures
3(e) and 3(f)). Figure 4 shows that the eﬀects of Epo on
thalassemic RBC and platelets are dose-dependent.
Oxidative stress can be induced in normal RBC and
platelets by treatment with oxidants [22, 27]. To study the
eﬀect of Epo on such cells, normal blood samples were
treatedfor30minwithdiﬀerent concentrations of H2O2 and
then were treated or not with Epo (2U/ml) for an additional
2hrs.Figure 5 shows that H2O2dose-dependently increased4 Anemia
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Figure 2: The kinetics of EPO eﬀect on ROS generation by RBC and platelets. A diluted blood sample obtained from a thalassemia patient
was stained with DCF, washed, and then incubated at room temperature with Epo (1U/ml). Fluorescence was measured by ﬂow cytometry
at the indicated time points. The time-related changes in the mean ﬂuorescent intensity (MFI) of each population are indicated.
ROSandthatEposigniﬁcantlyinhibitedthiseﬀectofH2O2in
both normal RBC and platelets.
In vivo, oxidative stress in RBC is associated with
accelerated senescence, increased intrasvascular hemolysis,
and mainly extravascular hemolysis [30]. We correlated the
eﬀects of Epo on ROS and GSH of RBC with its eﬀects
on calcein staining and PS exposure, markers of senescence
[18, 31], and susceptibility to undergo hemolysis and
phagocytosis. Thalassemic RBC were diluted and incubated
in their autologous plasma for 3 days with or without Epo
(2U/ml). The results (Figure 6) show that concomitant with
the decrease in ROS (Figure 6(a)) and the increase in GSH
(Figure 6(b)), Epo treatment increased their staining with
calcein(by190%)(Figure 6(c))anddecreasedtheirexposure
of PS (Figure 6(d)) (by 40%), hemolysis (70%) (Figure 6(e))
and phagocytosis (80%) (Figure 6(f)). These results were
highly signiﬁcant (P<. 005).
The in vivo eﬀect of Epo was determined in thalassemic
mice. Blood samples were drawn prior and 2 hours after i.p.
injection of Epo (5000U/kg), and RBC were analyzed for
ROS,GSHsandlipidperoxidation.Theresultsdemonstrated
that Epo treatment signiﬁcantly reduced ROS and lipid per-
oxidation and enhanced the GSH level (Figure 7), indicating
its ability to ameliorate oxidative stress parameters in vivo.
4. Discussion
In the β-hemoglobinopathies, β-thalassemia, and sickle cell
disease, although the primary lesion is in the β-globin
gene, the damage to the RBC is mediated in part by
oxidative stress [32, 33]. It has been previously shown that
in these diseases RBC are at oxidative stress as a result of
their unstable Hb and iron overload, caused by increased
absorption and blood transfusions [34, 35]. Using ﬂow
cytometry, we demonstrated higher ROS generation and
lower GSH content in these cells compared with normal
RBC at basal level, as well as following oxidative insult,
such as treatment with H2O2 [22, 36]. These eﬀects were
associated with RBC membrane changes, including lipid
peroxidation and externalization of PS [37, 38]a n dr e s u l t e d
in increased susceptibility to hemolysis and to phagocytosis
by macrophages [24], resulting in short survival of the
RBC in the circulation and subsequently in chronic anemia.
Oxidative stress was also found in the platelets of these
patients [22]. Since oxidative stress has been associated
with platelets’ activation [39], this may explain, in part,
the tendency of these patients to develop thromboembolic
complications [23].
We now report that Epo can ameliorate the oxidative
stress and some of its consequences in RBC and platelets in
thalassemia. Epo is being used to treat chronic anemia in
a variety of clinical conditions, such as the myelodysplastic
syndrome[40],oncologypatientsundergoingchemotherapy
[4] and patients with chronic renal failure undergoing
hemodialysis [5–7]. Although the main eﬀect of this treat-
ment is to increase the RBC mass by stimulating erythro-
poiesis, some studies suggest that Epo may also directly
aﬀect mature RBC: Myssina et al. [20] have shown that Epo
inhibits RBC Ca2+ channels with subsequent reduction in
PS exposure, and that intravenous administration of Epo
to dialysis patients decreased within 4hrs the frequency of
RBC with exposed PS. Clinical data in such patients further
revealed that Epo acts as a survival factor for mature RBC by
extending their life [17].
In β-thalassemia, Epo treatment was shown to improve
the state of anemia [8, 11, 14]. The rational of this treatment
in thalassemia is twofold: to stimulate erythropoiesis and to
elevate the production of fetal Hb; the latter compensates
for the lack or reduced content of HbA [41]. However, in
thesepatientsEpostimulatesthalassemicerythropoiesiswith
production of abnormal RBC having excess α-globin chains,
membrane damage, and short survival. As for stimulation of
fetal Hb, contradictory results were reported [8, 42, 43]. Our
ﬁndings raise the possibility that Epo administration may
beneﬁt thalassemic patients also by reducing oxidative stress
and thereby prolonging the survival of their RBC as well as
lowering the state of activation of their platelets.
Epo is known to have a protective eﬀect in nonerythroid
cells, such as neuronal cells and cardiomyocytes [44]. For
example, signiﬁcant improvement was demonstrated inAnemia 5
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Figure 3: Eﬀect of Epo on the oxidative stress of RBC and platelets from thalassemic patients. Diluted blood samples were untreated with
or without 1U/ml Epo for 3hrs at 37◦C, then stimulated (a, b) or not (c, d) with 1mM H2O2 for 15min, and assayed for ROS. RBC (e) and
platelets (f) treated with or without Epo were also assayed for GSH. The results, presented as the average (N = 11) of the mean ﬂuorescence
index (MFI) ± SD, show a decrease in ROS (P<. 05) and an increase in GSH (P<. 05) following Epo treatment.
stroke patients who were administered Epo within 8hrs
of the onset of symptoms [45]. The mechanism of Epo-
induced protection in nonerythroid cells was reported to
involve a number of signaling pathways, including the Jak-
2/STAT [46], a crucial pathway of its erythropoietic eﬀect
[47]. However, the eﬀect of Epo in non-erythroid cells is
probably unrelated to its inﬂuence in erythropoiesis. The
eﬀect on erythropoiesis requires the continuous presence
of Epo, whereas a brief exposure is suﬃcient for neu-
roprotection [48]. Consequently, desialylated Epo, which
has the same aﬃnity to the Epo receptor (EpoR) but a
reduced erythropoietic eﬀect due to its short life-span,
remains neuroprotective [49]. Carbamylated Epo (CEpo),
another Epo analog, which does not bind to EpoR and6 Anemia
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Figure 4: The Epo dose-eﬀect relationship on ROS and GSH of thalassemic RBC and platelets. Diluted blood samples were exposed to
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Figure 5: Eﬀect of Epo on ROS production by H2O2-stimulated normal RBC and platelets. Diluted blood samples were treated with the
indicated concentrations of H2O2 for 30min, then incubated with or without Epo (2U/ml) for additional 2hrs, washed and assayed for
ROS. The results show the average (N = 3) mean ﬂuorescence index (MFI) ± SD.
lacks erythropoietic activity, confers neuroprotection and
cardioprotection against various cellular injuries [50–52].
Our preliminary results suggest that for the antioxidative
eﬀect in thalassemic RBC continuous Epo exposure is not
required and that CEpo is active (data not shown).
The receptor complex mediating the Epo protective
eﬀects in non-erythroid cells diﬀers from EpoR with respect
to the aﬃnity for Epo, molecular weight, and associated
proteins (reviewed in [53]). It was suggested that the
protective eﬀect of CEpo is mediated through a hetero-
receptor complex comprising of EpoR and a β-receptor
subunit (CD131), a signal-transducing subunit shared by
receptors to several cytokines [53].
Several reports attributed the protection by Epo of non-
erythroid cells to its anti-oxidative eﬀect, for example, [54–
58]. In addition, Epo has been also shown to aﬀect oxidative
parameters of mature RBC. Thus, starvation, which was
found to deplete the endogenous Epo, increased lipid per-
oxidation of the RBC membrane, whereas administration of
Epo reversed the eﬀect [59]. Epo treatment of hemodialysis
patients resulted in reduced lipid peroxidation and enhanced
SOD, catalase, and other antioxidant activities [60–65].Anemia 7
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Figure 6: The long-term eﬀects of Epo on RBC oxidative markers, ageing, and susceptibility to hemolysis, and phagocytosis. Thalassemic
RBC were diluted to 4 × 106/ml with their plasma and incubated with or without Epo (2U/ml) for 3 days. The cells were then harvested and
assayed for ROS (a), GSH (b), calcein (c), external phosphatidylserine (PS) (d), hemolysis (e) and phagocytosis (f) as detailed in Section 2.
The results in (a), (b) and (c) are presented the mean ﬂuorescence index (MFI), in (d) as the percentage of PS positive RBC, and in (e) and
(f) as the percentage of hemolysed and phagocytosed RBC, respectively, compared to the RBC input. The data are the average ± SD of 4
experiments performed with blood samples derived from diﬀerent patients.
These eﬀects of Epo could be related to its inﬂuence dur-
ing RBC production (erythropoiesis). Moreover, improved
antioxidant status following Epo treatment of newborn
rabbits was suggested to be caused indirectly by utilization
of the oxidative active serum iron by developing erythroid
precursors, thus making it unavailable for generation of
oxygen radicals via the Fenton reaction [66]. In the present
study we report a direct eﬀect of Epo on RBC, which is
unrelated to erythropoiesis. The eﬀects were observed in
vitro by incubating peripheral blood RBC with Epo as well as
shortly (3hrs) after injection of Epo into β-thalassemic mice.
These results are in agreement with reports by Datta et al.
who showed that Epo has multiple eﬀects on mature RBC,
including an anti-oxidative one [37, 67–72].
The mechanism underlying the short-term eﬀect of Epo
on the oxidative stress of mature RBC is not clear. Epo aﬀects
erythroid cells through their surface Epo-R, but mature RBC
(and reticulocytes) appear to lack Epo-R [73, 74]. However,
it was reported that Scatchard plot analysis of radio-labeled-
Epo binding disclosed a low, albeit detectable, number of
Epo-binding sites on RBC with high aﬃnity to Epo [20]
that was similar to that of the Epo-R of early erythroid8 Anemia
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Figure 7: Eﬀect of Epo on thalassemic mice. Heterozygous β-
thalassemic intermedia (Hbbth3/+)m i c e( N = 4) with low
hemoglobin levels (7–9g/dL) were inoculated (i.p) with Epo
(5000U/kg). Before (Without Epo) and 2hrs after (With Epo)
injection, blood was drawn and RBC were assayed. The changes
in the indicated parameters are shown. Values of untreated mice
(Without Epo) were taken as 100%.
progenitors [73]. Interaction of Epo with the mature RBC
membrane was also reported by Baciu et al. [75]. To probe
the possibility that Epo-R is involved in mediating the eﬀect
of Epo on RBC, we inhibited Jak-2, a crucial step in the
signaltransductionpathwayofEpo-R,byJakinhibitorI[76].
Treatment of thalassemic RBC with this inhibitor did not
inhibit the antioxidative eﬀect of Epo (data not shown).
T h ep r o t e c t i v ee ﬀect of Epo may be mediated through
scavenging activity in the extracellular milieu: Epo contains
more basic than acidic amino acids and many charged
residues [77] that may act as a “sink” for ROS (e.g., hydroxyl
radicals) [78]. Moreover, Epo is a highly sialidated glycopro-
tein [79]. It has been recently reported that mucin, a typical
sialic acid containing high-molecular weight glycoprotein,
is an anti-oxidant and that sialic acid is crucial for this
activity [80]. Sialic acid may also function intracellularly.
Oetke et al. [81], using human hematopoietic cell lines
which are hyposialylated due to a deﬁciency in de novo
sialic acid biosynthesis, demonstrated eﬃcient uptake and
incorporation of free sialic acid. Other studies reported that
human thalassemic RBC have a lower content of sialic acid
than normal RBC [82, 83], and that sialic acid can be taken
up by human RBC [84, 85]. In our experiments, using
several methodologies, Epo, at the concentrations tested in
this study, did not demonstrate any ROS scavenging activity
in a cell-free system (data not shown).
In the present study we report the antioxidative potential
of Epo on RBC and platelets. Indeed, its activity was
demonstrated at concentrations far above normal serum
levels, but this does not rule out a role at physiologi-
cal concentrations—continuous, accumulative subthreshold
eﬀects, which could not be detected by the methodology
used, may be of physiological importance. Epo is obviously
inappropriate as an anti-oxidative drug: it is less potent
and much more expensive than other anti-oxidants and, in
addition, has to be administrated by injection. Nevertheless,
underconditionswhenitslevelsareveryhigh,suchasduring
severe anemia, for example, following massive bleeding or in
aplastic anemia, or following its administration to patients
on hemodialysis or chemotherapy, its potential protective
eﬀect as an antioxidant on RBC and platelet survival should
be considered.
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